IMAAVY™
(nipocalimab-aahu)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
IMAAVY™ (nipocalimab-aahu)
Medical Information
IMAAVY - Latex Content
Last Updated: 05/29/2025
LATEX CONTENT
- Please refer to local labeling for relevant information regarding the use of IMAAVY.
- The immediate containers or excipients of the IMAAVY dosage forms and strengths below are not made with natural rubber latex.1
- IMAAVY 300 mg/1.62 mL (185 mg/mL) in a single-dose vial
- IMAAVY 1,200 mg/6.5 mL (185 mg/mL) in a single-dose vial
The immediate containers or excipients do not contain latex as an ingredient; however, the company cannot guarantee that these materials do not come in contact with latex during their manufacturing or packaging process (e.g. latex gloves).1
References
| 1 | Data on File. Technical Document - Patient Safety and Compliance Information of Nipocalimab (M281) IV FVP v1.0. Janssen Material Sciences; 2025. |